Start Community Clinic

CLIA Laboratory Citation Details

2
Total Citations
20
Total Deficiencyies
9
Unique D-Tags
CMS Certification Number 19D1071328
Address 5975 Federal Highway 80, Rayville, LA, 71269
City Rayville
State LA
Zip Code71269
Phone(318) 728-4368

Citation History (2 surveys)

Survey - December 10, 2019

Survey Type: Special

Survey Event ID: 60E011

Deficiency Tags: D0000 D2016 D2123 D2130 D2131 D6000 D6016 D0000 D2016 D2123 D2130 D2131 D6000 D6016

Summary:

Summary Statement of Deficiencies D0000 A PT Desk Review was performed on December 10, 2019. Start Community Clinic- 19D1071328 was found not in compliance with the following CONDITION LEVEL DEFICIENCIES: 42 CFR 493.803 CONDITION: Successful Participation 42 CFR 493.1403 CONDITION: Laboratories performing moderate complexity testing; Laboratory Director D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of proficiency testing results from the CMS-153, CMS-155D and American Association of Bioanalysts (AAB), the laboratory failed to successfully participate in proficiency testing as evidence by: 1. The laboratory failed to participate Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- in Event 3 of 2019 resulting in an unsatisfactory performance and a score of zero for White Blood Cell Differential (WBC Diff), Red Blood Cell (RBC), Hematocrit (HCT), Hemoglobin (HGB), White Blood Cell (WBC) and Platelets. Refer to D2123 2. The laboratory failed to achieve a score of at least 80% for Hematology analytes in two consecutive events, resulting in initial unsuccessful performance. Refer to D2130. 3. The laboratory failed to acieve an overall score of at least 80% for two consecutive events in the specialty of Hematology resulting in initial unsuccessful performance. Refer to D2131 D2123 HEMATOLOGY CFR(s): 493.851(c) Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3) The laboratory participated in the previous two proficiency testing events. This STANDARD is not met as evidenced by: Based on a review of proficiency testing (PT) results, the laboratory failed to participate in Event 3 of 2019 resulting in an unsatisfactory performance and a score of zero for White Blood Cell Differential (WBC Diff), Red Blood Cell (RBC), Hematocrit (HCT), Hemoglobin (HGB), White Blood Cell (WBC) and Platelets. The findings are as follows: 1. Review of American Association of Bioanalysts (AAB) proficiency testing records and CASPER 155D report revealed the laboratory did not participate in Event 3 of 2019 for Hematology testing resulting in the following unsatisfactory scores: WBC Diff score of 0%. RBC score of 0%. HCT score of 0%. HGB score of 0%. WBC score of 0%. Platelets score of 0%. D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of proficiency testing results from the CMS-155D and American Association of Bioanalysts (AAB), the laboratory failed to achieve a score of at least 80% for Hematology analytes in two consecutive events, resulting in initial unsuccessful performance. Findings: 1. Review of proficiency testing records and the CMS 155D Report revealed the laboratory received a score of 0% for the following analytes resulting in initial unsuccessful performance: a. 2019 Event 3: Score of 0% for Red Blood Cell (RBC) b. 2019 Event 2: Score of 0% for Red Blood Cell (RBC) c. 2019 Event 3: Score of 0% for Hematocrit d. 2019 Event 2: Score of 0% for Hematocrit e. 2019 Event 3: Score of 0% for Hemoglobin f. 2019 Event 2: Score of 0% for Hemoglobin -- 2 of 3 -- D2131 HEMATOLOGY CFR(s): 493.851(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of proficiency testing records and CASPER Report 0155D, the laboratory failed to acieve an overall score of at least 80% for two consecutive events in the specialty of Hematology resulting in initial unsuccessful performance. Findings: 1. Review of proficiency testing records and Casper Report 0155D revealed the laboratory received unsatisfactory scores for the following two consecutive events in Hematolgy: a. 2019 Event 2: Score of 43% for Hematology b. 2019 Event 3: Score of 0% for Hematology D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on record review and interview with personnel, the Laboratory Director failed to provide overall management and direction for the laboratory. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: The laboratory director failed to ensure that proficiency testing samples are satisfactory as required. Findings: 1. The laboratory failed to participate in Event 3 of 2019 resulting in an unsatisfactory performance and a score of zero for White Blood Cell Differential (WBC Diff), Red Blood Cell (RBC), Hematocrit (HCT), Hemoglobin (HGB), White Blood Cell (WBC) and Platelets. Refer to D2123 2. The laboratory failed to achieve a score of at least 80% for Hematology analytes in two consecutive events, resulting in initial unsuccessful performance. Refer to D2130. 3. The laboratory failed to acieve an overall score of at least 80% for two consecutive events in the specialty of Hematology resulting in initial unsuccessful performance. Refer to D2131 -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - July 18, 2018

Survey Type: Standard

Survey Event ID: TKJ611

Deficiency Tags: D0000 D5421 D6013 D0000 D5421 D6013

Summary:

Summary Statement of Deficiencies D0000 A CERTIFICATION SURVEY was performed at Start Community Clinic - CLIA # 19D1071328 on July 18, 2018. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: Based on observation, record review, and interview with personnel, the laboratory failed to have complete performance specification verification studies for the Horiba Medical ABX Micros 60 Hematology analyzer. Findings: 1. Observation by surveyor during the laboratory tour on July 18, 2018 revealed the laboratory utilizes the Horiba Medical ABX Micros 60 Hematology analyzer for Complete Blood Count (CBC) testing. 2. In interview on July 18, 2018 at 9:40 am, Personnel 2 stated the Horiba Medical ABX Micros 60 Hematology analyzer was installed by the service representative in December 2017 and the laboratory started patient testing in January 2018. 3. Review of the laboratory's performance verification studies revealed the laboratory did perform accuracy, precision, reportable range and reference range studies; However, the studies were not reviewed and signed off by the Laboratory Director. 4. In interview on July 18, 2018 at 10:24 am, Personnel 3 (Technical Consultant) stated she reviewed the performance studies but she did not have the Laboratory Director sign off on the studies. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D6013 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(3)(ii) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(3) Ensure that-- (e)(3)(ii) Verification procedures used are adequate to determine the accuracy, precision, and other pertinent performance characteristics of the method; This STANDARD is not met as evidenced by: Based on observation, record review, and interview with laboratory personnel, the Laboratory Director failed to ensure that complete verification procedures were performed. Refer to D5421. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access